Semaglutide

Semaglutide was developed by Novo Nordisk in 2012 as a longer-acting alternative to liraglutide, designed to allow once-weekly dosing. What it is: Semaglutide is a synthetic 31-amino-acid peptide analogue of human GLP-1, modified with a C18 diacid chain to resist enzymatic degradation. It falls under the Metabolic category (brand names Ozempic, Wegovy, Rybelsus). Proposed Mechanisms & Research Findings: It is a selective GLP-1 receptor agonist that increases insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and acts on the brain to reduce appetite. Regulatory & Safety Status: It is FDA approved for Type 2 Diabetes (2017) and obesity/chronic weight management (2021). Sourcing must be done through licensed pharmacies; gray-market non-prescription compounds are unsafe. Athletic & Anti-Doping Status: It is under WADA monitoring but not prohibited. Athletes must ensure compliance with therapeutic use exemptions if required by specific organizations.